Human pluripotent stem cell–derived models and drug screening in CNS precision medicine
Year: 2019
Type: review
Abstract: Development of effective therapeutics for neurological disorders has historically been challenging partly because of lack of accurate model systems in which to investigate disease etiology and test new therapeutics at the preclinical stage. Human stem cells, particularly patient-derived induced pluripotent stem cells (iPSCs) upon differentiation, have the ability to recapitulate aspects of disease pathophysiology and are increasingly recognized as robust scalable systems for drug discovery. We review advances in deriving cellular models of human central nervous system (CNS) disorders using iPSCs along with strategies for investigating disease-relevant phenotypes, translatable biomarkers, and therapeutic targets. Given their potential to identify novel therapeutic targets and leads, we focus on phenotype-based, small-molecule screens employing human stem cell-derived models. Integrated efforts to assemble patient iPSC-derived cell models with deeply annotated clinicopathological data, along with molecular and drug-response signatures, may aid in the stratification of patients, diagnostics, and clinical trial success, shifting translational science and precision medicine approaches. A number of remaining challenges, including the optimization of cost-effective, large-scale culture of iPSC-derived cell types, incorporation of aging into neuronal models, as well as robustness and automation of phenotypic assays to support quantitative drug efficacy, toxicity, and metabolism testing workflows, are covered. Continued advancement of the field is expected to help fully humanize the process of CNS drug discovery.
DOI: 10.1111/nyas.14012
Authors: M. Catarina Silva, Stephen J. Haggarty
Institutions: Harvard University, Massachusetts General Hospital
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Funders: FRAXA Research Foundation, Association for Frontotemporal Degeneration, Stanley Medical Research Institute, National Institute on Aging, National Institute of Mental Health, National Human Genome Research Institute, National Institute of Neurological Disorders and Stroke, National Center for Complementary and Integrative Health
Awards: Genomics-Guided Characterization of iPS Cells from Common Mental Illnesses, Functional Genomics of Neuroplasticity in Schizophrenia, Neuropsychiatric Genome-Scale and RDOC Individualized Domains (N-GRID), Validation of Modulators of PGRN as Novel Therapeutics for Frontotemporal Dementi, Patient-Derived Cellular Models of Putative Antidepressants, Epigenomic Characterization of Alzheimer's Disease Neurons from iPSCs, Chemical Genomic Approaches to Neurobiology of DISC1, Autosomal Dominant FTLD Tauopathy Patient-Specific Stem Cell Models
OpenAlex ID: W2920816178
